Genmab Provides Update on Ofatumumab Development in Autoimmune Indications

On March 8, 2016 Genmab A/S (Nasdaq Copenhagen: GEN) reported an update on development plans for ofatumumab in autoimmune indications focusing on relapsing multiple sclerosis following the transfer of the rights to ofatumumab in this disease area from GlaxoSmithKline (GSK) to Novartis at the end of 2015 (Press release, Genmab, MAR 8, 2016, View Source [SID:1234509401]). Phase III studies are expected to be initiated by Novartis with the subcutaneous formulation of ofatumumab as therapy for patients with relapsing multiple sclerosis during the second half of 2016.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase III study of the subcutaneous formulation of ofatumumab in pemphigus vulgaris, which was started by GSK will be discontinued to focus on relapsing multiple sclerosis. The decision to discontinue the trial was not related to any safety or tolerability concerns. There are no current plans to develop ofatumumab in neuromyelitis optica.

"We are very pleased with Novartis’ commitment to move the development of ofatumumab forward in multiple sclerosis and look forward to the initiation of the Phase III studies in the second half of this year," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About Ofatumumab (Arzerra)
Ofatumumab is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of chronic lymphocytic leukemia (CLL) cells and normal B lymphocytes.

In the United States, Arzerra is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. Arzerra is also approved in the U.S. as extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. In the European Union, Arzerra is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. In more than 50 countries worldwide, Arzerra is also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab.

Please see full Prescribing Information, including Boxed WARNING for Arzerra (ofatumumab).

The subcutaneous formulation of ofatumumab is also being investigated by Novartis in multiple sclerosis. The use of ofatumumab in multiple sclerosis is investigational and is not currently approved in any market.

Arzerra is marketed under a collaboration agreement between Genmab and Novartis.

Ipsen and PeptiMimesis announce a research partnership in oncology

March 8, 2016 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, and PeptiMimesis, a start-up from an INSERM (French National Institute of Health and Medical Research) and Strasbourg University spin-off project, funded by SATT Conectus Alsace, reported the signature of a research partnership and a licensing option for the development and marketing of novel therapeutic peptides in oncology (Press release, Ipsen, MAR 8, 2016, View Source [SID:1234509421]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ipsen will combine its expertise in peptide design and development with PeptiMimesis knowledge in the identification of transmembrane peptides and intracellular signaling. The target receptor is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation.

"PeptiMimesis is extremely proud that its innovative approach is recognized by Ipsen, a prominent partner in therapeutic peptides. We are convinced that this initial collaboration will pave the way for a series of partnerships, given the tremendous possibilities of targeting transmembrane receptors," said Pascal Neuville, Chief Executive Officer of Domain Therapeutics, co-founding company of PeptiMimesis and Chairman of PeptiMimesis. "This partnership is the result of more than 15 years of research that reached the validation stage thanks to the support of SATT Conectus. Work on the project will now continue in close cooperation between my laboratory, PeptiMimesis and Ipsen," added Dominique Bagnard, Ph.D., PeptiMimesis scientific founder.

Claude Bertrand, Executive Vice President, Research & Development and Chief Scientific Officer of Ipsen, commented: "We have been working with Dominique Bagnard’s team since 2014 to assess the potential of transmembrane targeting of a specific receptor identified as involved in cancer development. We are delighted to continue our involvement with the young start-up PeptiMimesis to combine our strengths and expertise to identify and develop new treatments for cancer patients. The project aligns perfectly with our research strategy and extends our expertise in peptides."

Under the terms of the agreement, Ipsen and PeptiMimesis will work closely together to move the project forward towards clinical development. PeptiMimesis will receive financial support from Ipsen for the research phases, as well as milestone payments associated to the program. In the event the option is exercised, Ipsen could make further potential payments to PeptiMimesis at development, regulatory and commercial milestones, as well as royalty payments on worldwide annual net sales.

8-K – Current report

On March 8, 2016 Bio-Path Holdings, Inc., (NASDAQ: BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, reported that it has entered a sponsored research agreement with The University of Texas MD Anderson Cancer Center ("MD Anderson") to evaluate Bio-Path’s clinical pipeline for its ability to modulate pancreatic cancer (Filing, 8-K, Bio-Path Holdings, MAR 8, 2016, View Source [SID:1234509416]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path’s lead product candidate, which is currently in a Phase II study for blood cancers.

Jason Fleming, M.D., F.A.C.S., professor of surgical oncology within the division of surgery at MD Anderson, will serve as the study’s principal investigator. Dr. Fleming initiated and developed the first direct xenograft program in gastrointestinal cancer. These xenografts were derived from malignant pancreatic tumors that Dr. Fleming and his surgical colleagues removed from patients at MD Anderson. Dr. Fleming is also director of the tissue acquisition and biorepository core for the Pancreas Cancer Research Program at MD Anderson, and is a board certified pancreatic surgeon.

"We are honored to collaborate with Dr. Fleming," said Peter Nielsen, President and Chief Executive Officer of Bio-Path. "His experience working with pancreatic xenografts makes him uniquely qualified to lead this study. We look forward to assessing whether Bio-Path’s drug candidates work in this ex vivo model before potentially moving into animal studies."

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Scynexis has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Scynexis, 2017, MAR 7, 2016, View Source [SID1234521749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

(Filing, Annual, Compugen, 2015, MAR 7, 2016, View Source [SID:1234509392])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!